Certara, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Certara, Inc. on March 5, 2025, reporting events occurring on March 3, 2025. The filing addresses a change in senior management within the Company's Drug Development Solutions division.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
Dr. Patrick F. Smith, President of Certara Drug Development Solutions, stepped down from that role effective March 3, 2025. He will remain employed by the Company in a senior advisory and scientific role.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Dr. Patrick F. Smith's departure as President of Certara Drug Development Solutions is effective March 3, 2025.
- Dr. Smith remains with the Company in a senior advisory and scientific capacity.
- No financial results or strategic guidance were disclosed in this specific filing.